<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.3.340">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">


<title>lung-tumors</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
div.columns{display: flex; gap: min(4vw, 1.5em);}
div.column{flex: auto; overflow-x: auto;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
ul.task-list li input[type="checkbox"] {
  width: 0.8em;
  margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
  vertical-align: middle;
}
</style>


<script src="lung-tumors_files/libs/clipboard/clipboard.min.js"></script>
<script src="lung-tumors_files/libs/quarto-html/quarto.js"></script>
<script src="lung-tumors_files/libs/quarto-html/popper.min.js"></script>
<script src="lung-tumors_files/libs/quarto-html/tippy.umd.min.js"></script>
<script src="lung-tumors_files/libs/quarto-html/anchor.min.js"></script>
<link href="lung-tumors_files/libs/quarto-html/tippy.css" rel="stylesheet">
<link href="lung-tumors_files/libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="lung-tumors_files/libs/bootstrap/bootstrap.min.js"></script>
<link href="lung-tumors_files/libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="lung-tumors_files/libs/bootstrap/bootstrap.min.css" rel="stylesheet" id="quarto-bootstrap" data-mode="light">


</head>

<body class="fullcontent">

<div id="quarto-content" class="page-columns page-rows-contents page-layout-article">

<main class="content" id="quarto-document-content">



<p><img src="img%5CLung-Tumors0.jpg" class="img-fluid"></p>
<section id="lung-tumors" class="level1">
<h1>Lung Tumors</h1>
</section>
<section id="serdar-balci-md" class="level1">
<h1>Serdar BALCI, MD</h1>
</section>
<section id="metastasis-to-the-lung" class="level1">
<h1>METASTASIS TO THE LUNG</h1>
<p><strong>metastatic tumors form multiple discrete nodules scattered throughout all lobes</strong></p>
<p><img src="img%5CLung-Tumors1.png" class="img-fluid"></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
<p><img src="img%5CLung-Tumors2.png" class="img-fluid"></p>
<p><strong>Metastases to the lung</strong></p>
<p><strong>diffusely infiltrating the lung parenchyma (lymphangitic spread)</strong></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
</section>
<section id="primary-lung-tumors" class="level1">
<h1>PRIMARY LUNG TUMORS</h1>
</section>
<section id="primary-lung-tumors-1" class="level1">
<h1>Primary Lung Tumors</h1>
<ul>
<li><strong>95% of primary lung tumors are carcinomas</strong></li>
<li><strong>5% →</strong>
<ul>
<li><strong>Carcinoids</strong></li>
<li><strong>Mesenchymal malignancies, fibrosarcomas, leiomyomas</strong></li>
<li><strong>Lymphomas</strong></li>
<li><strong>Other benign lesions</strong></li>
</ul></li>
</ul>
</section>
<section id="pulmonary-hamartoma" class="level1">
<h1>Pulmonary Hamartoma</h1>
<ul>
<li><strong>Most common benign tumor</strong>
<ul>
<li><strong>Spherical</strong></li>
<li><strong>Small (3 to 4 cm)</strong></li>
<li><strong>Coin lesion on chest radiographs</strong></li>
<li><strong>Mature cartilage, often admixed with fat, fibrous tissue, and blood vessels</strong></li>
<li><strong>Clonal cytogenic abnormalities show that it is a benign neoplasm</strong>
<ul>
<li><strong>Misnomer as hamartoma</strong></li>
</ul></li>
</ul></li>
</ul>
<p><img src="img%5CLung-Tumors3.png" class="img-fluid"></p>
</section>
<section id="lung-cancer" class="level1">
<h1>Lung cancer</h1>
<ul>
<li><strong>Carcinoma of the lung</strong></li>
<li><strong>Single most important cause of cancer-related deaths in industrialized countries</strong>
<ul>
<li><strong>Incidence among males is gradually decreasing, but it continues to increase among females</strong></li>
<li><strong>Women dying each year from lung cancer than from breast cancers</strong></li>
<li><strong>Causal relationship of cigarette smoking and lung cancer</strong></li>
</ul></li>
<li><strong>Peak incidence in 50s-60s</strong></li>
<li><strong>&gt;50% of patients already have distant metastatic disease</strong>
<ul>
<li><strong>1/4 have disease in the regional lymph nodes</strong></li>
</ul></li>
<li><strong>5-yr survival rate for all stages 16%</strong>
<ul>
<li><strong>Even localized to lung 45%</strong></li>
</ul></li>
</ul>
</section>
<section id="smoking-related-carcinomas" class="level1">
<h1>Smoking-related carcinomas</h1>
<ul>
<li><strong>Stepwise accumulation of a multitude of genetic abnormalities</strong></li>
<li><strong>Sequence of molecular changes is not random</strong>
<ul>
<li><strong>Follows a predictable sequence that parallels the histologic progression</strong></li>
</ul></li>
<li><strong>Early</strong>
<ul>
<li><strong>Inactivation of the putative tumor suppressor genes on (3p)</strong></li>
<li><strong>Found in benign bronchial epithelium of persons with lung cancer</strong></li>
<li><strong>In the respiratory epithelium of smokers without lung cancer</strong></li>
<li><strong>Field effect </strong></li>
</ul></li>
<li><strong>Late</strong>
<ul>
<li><strong>TP53 mutations or activation of the KRAS oncogene</strong></li>
</ul></li>
</ul>
</section>
<section id="nonsmoking-women-of-far-eastern-origin" class="level1">
<h1>Nonsmoking women of Far Eastern origin</h1>
<p><strong>Activating mutations of the epidermal growth factor receptor (EGFR)</strong></p>
<p><strong>Sensitive to agents that inhibit EGFR signaling</strong></p>
</section>
<section id="smoking" class="level1">
<h1>Smoking</h1>
<p><strong>90% of lung cancers occur in active smokers or those who stopped recently</strong></p>
<p><strong>Linear correlation has been recognized between the frequency of lung cancer and pack-years of cigarette smoking</strong></p>
<p><strong>60x greater among habitual heavy smokers (two packs a day for 20 years) than among nonsmokers</strong></p>
<ul>
<li><strong>Only 11% of heavy smokers develop lung cancer</strong>
<ul>
<li><strong>Other predisposing factors must be operative in the pathogenesis of this deadly disease</strong></li>
</ul></li>
<li><strong>Mutagenic effect of carcinogens is conditioned by hereditary (genetic) factors</strong>
<ul>
<li><strong>P-450 monooxygenase enzyme system</strong></li>
</ul></li>
<li><strong>Women have a higher susceptibility to carcinogens in tobacco than men</strong></li>
<li><strong>Cessation of smoking decreases the risk of developing lung cancer over time</strong>
<ul>
<li><strong>May never return to baseline levels</strong></li>
<li><strong>Genetic changes can persist for many years</strong></li>
</ul></li>
<li><strong>Passive smoking</strong>
<ul>
<li><strong>2x risk than nonsmokers</strong></li>
</ul></li>
<li><strong>Pipes and cigars also increases the risk</strong></li>
<li><strong>Miners</strong>
<ul>
<li><strong>Radioactive ores</strong></li>
<li><strong>Asbestos workers</strong></li>
<li><strong>Dusts containing arsenic, chromium, uranium, nickel, vinyl chloride, and mustard gas</strong></li>
</ul></li>
<li><strong>Exposure to asbestos</strong>
<ul>
<li><strong>5x risk in nonsmokers</strong></li>
<li><strong>55x risk in smokers</strong></li>
</ul></li>
</ul>
</section>
<section id="lung-cancers" class="level1">
<h1>LUNG CANCERS</h1>
</section>
<section id="spread-of-carcinoma-of-the-lung" class="level1">
<h1>Spread of Carcinoma of the Lung</h1>
<p><strong>Involvement of successive chains of nodes about the carina</strong></p>
<p><strong>Mediastinum</strong></p>
<p><strong>Neck (scalene nodes)</strong></p>
<p><strong>Clavicular regions</strong></p>
<p><strong>Distant metastases</strong></p>
<p><strong>Left supraclavicular node (Virchow node)</strong></p>
<p><strong>Pleural or pericardial space, leading to inflammation and effusion</strong></p>
</section>
<section id="carcinoma-of-the-lung" class="level1">
<h1>Carcinoma of the lung</h1>
<ul>
<li><strong>Compress or infiltrate the superior vena cava</strong>
<ul>
<li><strong>Vena cava syndrome</strong></li>
</ul></li>
<li><strong>Apical neoplasms may invade the brachial or cervical sympathetic plexus</strong>
<ul>
<li><strong>Severe pain in the distribution of the ulnar nerve</strong></li>
<li><strong>Horner syndrome</strong>
<ul>
<li><strong>Ipsilateral enophthalmos, ptosis, miosis, and anhidrosis</strong></li>
</ul></li>
<li><strong>Pancoast tumors</strong>
<ul>
<li><strong>Apical tumors</strong></li>
<li><strong>Pancoast syndrome</strong></li>
<li><strong>Destruction of the first and second ribs, thoracic vertebrae</strong></li>
</ul></li>
</ul></li>
<li><strong>Metastatic spread</strong>
<ul>
<li><strong>Brain</strong>
<ul>
<li><strong>Mental or neurologic changes</strong></li>
</ul></li>
<li><strong>Liver</strong>
<ul>
<li><strong>Hepatomegaly</strong></li>
</ul></li>
<li><strong>Bones</strong>
<ul>
<li><strong>Pain</strong></li>
</ul></li>
<li><strong>Adrenal</strong>
<ul>
<li><strong>Insufficiency is uncommon</strong></li>
</ul></li>
</ul></li>
<li><strong>NSCLCs carry a better prognosis than SCLCs</strong></li>
</ul>
</section>
<section id="paraneoplastic-syndromes" class="level1">
<h1>Paraneoplastic syndromes</h1>
<ul>
<li><strong>Hypercalcemia</strong>
<ul>
<li><strong>Parathyroid hormone–related peptide</strong></li>
</ul></li>
<li><strong>Cushing syndrome</strong>
<ul>
<li><strong>ACTH</strong></li>
</ul></li>
<li><strong>Syndrome of inappropriate secretion of antidiuretic hormone</strong></li>
<li><strong>Neuromuscular syndromes</strong>
<ul>
<li><strong>Myasthenic syndrome, peripheral neuropathy, and polymyositis</strong></li>
</ul></li>
<li><strong>Clubbing of the fingers and hypertrophic pulmonary osteoarthropathy</strong></li>
<li><strong>Coagulation abnormalities</strong>
<ul>
<li><strong>Migratory thrombophlebitis, nonbacterial endocarditis, and disseminated intravascular coagulation</strong></li>
</ul></li>
<li><strong>Hypercalcemia → squamous cell neoplasms</strong></li>
<li><strong>hematologic syndromes → adenocarcinomas</strong></li>
</ul>
</section>
<section id="histologic-types-of-lung-cancer" class="level1">
<h1>Histologic Types of Lung Cancer</h1>
<ul>
<li><strong>Four major histologic types</strong>
<ul>
<li><strong>Adenocarcinoma</strong></li>
<li><strong>Squamous cell carcinoma</strong></li>
<li><strong>Small cell carcinoma</strong></li>
<li><strong>Large cell carcinoma</strong></li>
<li><strong>Combination of histologic patterns</strong></li>
</ul></li>
<li><strong>Squamous cell and small cell carcinomas</strong>
<ul>
<li><strong>Strongest association with smoking</strong></li>
</ul></li>
</ul>
<p><img src="img%5CLung-Tumors4.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CLung-Tumors5.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>
<section id="until-recently-there-were-two-groups" class="level1">
<h1>Until recently there were two groups</h1>
<ul>
<li><strong>SCLC</strong>
<ul>
<li><strong>metastasised at the time of diagnosis</strong></li>
<li><strong>no surgery</strong></li>
<li><strong>chemotherapy w/wo radiotherapy </strong></li>
</ul></li>
<li><strong>Non–small cell lung cancer (NSCLC)</strong>
<ul>
<li><strong>surgery</strong></li>
</ul></li>
<li><strong>Now, targeted therapy has changed the field</strong>
<ul>
<li><strong>Cannot give a drug of adenoca to sq cell ca</strong></li>
</ul></li>
</ul>
</section>
<section id="personalized-lung-cancer-therapy" class="level1">
<h1>Personalized lung cancer therapy</h1>
<ul>
<li><strong>Mutations</strong>
<ul>
<li><strong>EGFR, K-RAS</strong></li>
<li><strong>EGFR and K-RAS mutations are mutually exclusive</strong></li>
<li><strong>in 30% of adenocarcinomas</strong></li>
</ul></li>
<li><strong>Translocations</strong>
<ul>
<li><strong>EML4-ALK tyrosine kinase fusion genes</strong></li>
<li><strong>ROS-1</strong></li>
</ul></li>
<li><strong>Gene amplifications</strong>
<ul>
<li><strong>c-MET tyrosine kinase gene amplifications</strong></li>
</ul></li>
</ul>
<p><strong>4-6% of adenocarcinomas</strong></p>
<p><strong>Targeted with tyrosine kinase inhibitors</strong></p>
</section>
<section id="carcinomas-of-the-lung" class="level1">
<h1>Carcinomas of the lung</h1>
<ul>
<li><strong>Begin as small mucosal lesions</strong></li>
<li><strong>Firm and gray-white</strong></li>
<li><strong>May arise as intraluminal masses</strong>
<ul>
<li><strong>Invade the bronchial mucosa</strong></li>
</ul></li>
<li><strong>Form large bulky masses</strong>
<ul>
<li><strong>Pushing into adjacent lung parenchyma</strong></li>
</ul></li>
<li><strong>Some large masses undergo cavitation</strong>
<ul>
<li><strong>Secondary to central necrosis</strong></li>
<li><strong>Areas of hemorrhage</strong></li>
</ul></li>
<li><strong>May extend to the pleura</strong>
<ul>
<li><strong>Invade the pleural cavity and chest wall</strong></li>
</ul></li>
<li><strong>Spread to adjacent intrathoracic structures</strong></li>
<li><strong>Distant spread via lymphatics or hematogenous route</strong></li>
</ul>
</section>
<section id="squamous-cell-carcinomas" class="level1">
<h1>SQUAMOUS CELL CARCINOMAS</h1>
</section>
<section id="squamous-cell-carcinomas-1" class="level1">
<h1>Squamous cell carcinomas</h1>
<p><strong>More common in men than in women</strong></p>
<p><strong>Closely correlated with a smoking history</strong></p>
<p><strong>Centrally in major bronchi</strong></p>
<p><strong>Spread to local hilar nodes</strong></p>
<p><strong>Disseminate outside the thorax later than other histologic types</strong></p>
<p><strong>Large lesions, central necrosis, cavitation</strong></p>
<p><strong>Preneoplastic lesions, may last for several years</strong></p>
<p><strong>central squamous cell carcinoma has completely obstructed the lumen of the right main-stem bronchus. Metastatic tumor deposits are evident in both lungs</strong></p>
<p><img src="img%5CLung-Tumors6.png" class="img-fluid"></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
<ul>
<li><strong>Dysplasia</strong>
<ul>
<li><strong>Atypical cells may be identified in cytologic smears of sputum or in bronchial lavage fluids or brushings</strong></li>
<li><strong>Lesion is asymptomatic and undetectable on radiographs</strong></li>
</ul></li>
<li><strong>Tumor mass</strong>
<ul>
<li><strong>Obstruct the lumen of a major bronchus</strong></li>
<li><strong>Produce distal atelectasis and infection</strong></li>
</ul></li>
</ul>
<p><img src="img%5CLung-Tumors7.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CLung-Tumors8.png" class="img-fluid"></p>
<p><strong>Goblet cell hyperplasia</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CLung-Tumors9.png" class="img-fluid"></p>
<p><strong>Basal cell (reserve cell) hyperplasia</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CLung-Tumors10.png" class="img-fluid"></p>
<p><strong>Squamous metaplasia</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CLung-Tumors11.png" class="img-fluid"></p>
<p><strong>Squamous dysplasia</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CLung-Tumors12.png" class="img-fluid"></p>
<p><strong>Carcinoma in situ</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CLung-Tumors13.png" class="img-fluid"></p>
<p><strong>invasive squamous carcinoma</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CLung-Tumors14.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CLung-Tumors15.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>
<section id="adenocarcinoma" class="level1">
<h1>ADENOCARCINOMA</h1>
</section>
<section id="adenocarcinoma-1" class="level1">
<h1>Adenocarcinoma</h1>
<ul>
<li><strong>Usually more peripherally located, many with a central scar</strong>
<ul>
<li><strong>May occur as central lesions also</strong></li>
</ul></li>
<li><strong>Most common type of lung cancer in women and nonsmokers</strong></li>
<li><strong>Grow slowly</strong></li>
<li><strong>Form smaller masses than other subtypes</strong></li>
<li><strong>Tend to metastasize widely at an early stage</strong></li>
</ul>
<p><strong>Adenocarcinomas of the lung arise most commonly in the periphery</strong></p>
<p><img src="img%5CLung-Tumors16.png" class="img-fluid"></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
</section>
<section id="bronchioalveolar-stem-cells" class="level1">
<h1>Bronchioalveolar stem cells</h1>
<ul>
<li><strong>At bronchioloalveolar duct junction</strong></li>
<li><strong>Peripheral lung injury</strong></li>
<li><strong>Multipotent BASCs undergo expansion</strong></li>
<li><strong>Replenish the normal cell types</strong>
<ul>
<li><strong>Bronchiolar Clara cells and alveolar cells</strong></li>
</ul></li>
<li><strong>Facilitate epithelial regeneration</strong></li>
<li><strong>BASCs have initiating oncogenic event</strong>
<ul>
<li><strong>Somatic K-RAS mutation</strong></li>
</ul></li>
<li><strong>Results in pulmonary adenocarcinoma</strong></li>
</ul>
</section>
<section id="adenocarcinoma-2" class="level1">
<h1>Adenocarcinoma</h1>
<ul>
<li><strong>Histologic examination</strong>
<ul>
<li><strong>Acinar (gland-forming)</strong></li>
<li><strong>Papillary</strong></li>
<li><strong>Mucinous</strong>
<ul>
<li><strong>Often multifocal and may manifest as pneumonia-like consolidation</strong></li>
</ul></li>
<li><strong>Solid</strong>
<ul>
<li><strong>Requires demonstration of intracellular mucin production by special stains</strong></li>
</ul></li>
</ul></li>
<li><strong>Histologic examination</strong>
<ul>
<li><strong>Acinar (gland-forming)</strong></li>
<li><strong>Papillary</strong></li>
<li><strong>Mucinous</strong>
<ul>
<li><strong>Formerly mucinous bronchioloalveolar carcinoma</strong></li>
<li><strong>Often multifocal and may manifest as pneumonia-like consolidation</strong></li>
</ul></li>
<li><strong>Solid</strong>
<ul>
<li><strong>Requires demonstration of intracellular mucin production by special stains</strong></li>
</ul></li>
</ul></li>
</ul>
</section>
<section id="precursor-of-adenocarcinoma" class="level1">
<h1>Precursor of adenocarcinoma</h1>
<ul>
<li><strong>Squamous metaplasia and dysplasia may be present near adenocarcinomas</strong>
<ul>
<li><strong>But they are not the precursor lesions for this tumor</strong></li>
</ul></li>
<li><strong>Precursor of peripheral adenocarcinomas:</strong>
<ul>
<li><span style="color:#FF0000">Atypical adenomatous hyperplasia (AAH)</span></li>
<li><span style="color:#FF0000">Progresses to adenocarcinoma in situ</span></li>
</ul></li>
<li><strong>Minimally invasive adenocarcinoma</strong>
<ul>
<li><strong>&lt;3 cm and invasive component ≤5 mm</strong></li>
</ul></li>
<li><strong>Invasive adenocarcinoma</strong>
<ul>
<li><strong>Tumor of any size, invaded &gt;5 mm</strong></li>
</ul></li>
<li><strong>Squamous metaplasia and dysplasia may be present near adenocarcinomas</strong>
<ul>
<li><strong>But they are not the precursor lesions for this tumor</strong></li>
</ul></li>
<li><strong>Precursor of peripheral adenocarcinomas:</strong>
<ul>
<li><strong>Atypical adenomatous hyperplasia (AAH)</strong></li>
<li><strong>Progresses to adenocarcinoma in situ</strong>
<ul>
<li><strong>Formerly bronchioloalveolar carcinoma</strong></li>
</ul></li>
</ul></li>
<li><strong>Minimally invasive adenocarcinoma</strong>
<ul>
<li><strong>&lt;3 cm and invasive component ≤5 mm</strong></li>
</ul></li>
<li><strong>Invasive adenocarcinoma</strong>
<ul>
<li><strong>Tumor of any size, invaded &gt;5 mm</strong></li>
</ul></li>
</ul>
</section>
<section id="atypical-adenomatous-hyperplasia" class="level1">
<h1>Atypical adenomatous hyperplasia</h1>
<ul>
<li><strong>Well-demarcated focus of epithelial proliferation</strong></li>
<li><strong>Cuboidal to low-columnar cells</strong></li>
<li><strong>Cytologic atypia of variable degree</strong>
<ul>
<li><strong>Hyperchromasia, pleomorphism, prominent nucleoli</strong></li>
</ul></li>
<li><strong>Monoclonal</strong></li>
<li><strong>K-RAS mutations</strong></li>
</ul>
<p><img src="img%5CLung-Tumors17.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>
<section id="adenocarcinoma-in-situ" class="level1">
<h1>Adenocarcinoma in situ</h1>
<ul>
<li><p><strong>Involves peripheral parts of the lung, as a single nodule</strong></p></li>
<li><p><strong>3 cm or less</strong></p></li>
<li><p><strong>Growth along preexisting structures, and preservation of alveolar architecture</strong></p></li>
<li><p><strong>May be nonmucinous, mucinous, or mixed</strong></p></li>
<li><p><strong>Grow in a monolayer along the alveolar septa</strong></p>
<ul>
<li><strong>Lepidic growth pattern</strong></li>
</ul></li>
<li><p><strong>No destruction of alveolar architecture</strong></p></li>
<li><p><strong>No stromal invasion with desmoplasia</strong></p></li>
<li><p><strong>Formerly called bronchioloalveolar carcinoma</strong></p></li>
<li><p><strong>Involves peripheral parts of the lung, as a single nodule</strong></p></li>
<li><p><strong>3 cm or less</strong></p></li>
<li><p><strong>Growth along preexisting structures, and preservation of alveolar architecture</strong></p></li>
<li><p><strong>May be nonmucinous, mucinous, or mixed</strong></p></li>
<li><p><strong>Grow in a monolayer along the alveolar septa</strong></p>
<ul>
<li><strong>Lepidic growth pattern</strong></li>
</ul></li>
<li><p><strong>No destruction of alveolar architecture</strong></p></li>
<li><p><strong>No stromal invasion with desmoplasia</strong></p></li>
</ul>
<p><img src="img%5CLung-Tumors18.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>
<section id="adenocarcinoma-3" class="level1">
<h1>ADENOCARCINOMA</h1>
<p><img src="img%5CLung-Tumors19.png" class="img-fluid"></p>
<p><strong>Gland-forming adenocarcinoma; inset shows thyroid transcription factor 1 (TTF-1) positivity, which is seen in a majority of pulmonary adenocarcinomas</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>
<section id="personalized-lung-cancer-therapy-1" class="level1">
<h1>Personalized lung cancer therapy</h1>
<ul>
<li><strong>Mutations</strong>
<ul>
<li><strong>EGFR, K-RAS</strong></li>
<li><strong>EGFR and K-RAS mutations are mutually exclusive</strong></li>
<li><strong>in 30% of adenocarcinomas</strong></li>
</ul></li>
<li><strong>Translocations</strong>
<ul>
<li><strong>EML4-ALK tyrosine kinase fusion genes</strong></li>
<li><strong>ROS-1</strong></li>
</ul></li>
<li><strong>Gene amplifications</strong>
<ul>
<li><strong>c-MET tyrosine kinase gene amplifications</strong></li>
</ul></li>
</ul>
<p><strong>4-6% of adenocarcinomas</strong></p>
<p><strong>Targeted with tyrosine kinase inhibitors</strong></p>
</section>
<section id="large-cell-carcinomas" class="level1">
<h1>LARGE CELL CARCINOMAS</h1>
</section>
<section id="large-cell-carcinomas-1" class="level1">
<h1>Large cell carcinomas</h1>
<ul>
<li><strong>Undifferentiated malignant epithelial tumors</strong></li>
<li><strong>Lack the cytologic features of small cell carcinoma</strong></li>
<li><strong>No glandular or squamous differentiation</strong></li>
<li><strong>Large nuclei, prominent nucleoli, and a moderate amount of cytoplasm</strong></li>
<li><strong>On ultrastructural examination</strong>
<ul>
<li><strong>Minimal glandular or squamous differentiation is common</strong></li>
</ul></li>
</ul>
</section>
<section id="neuroendocrine-tumors" class="level1">
<h1>NEUROENDOCRINE TUMORS</h1>
</section>
<section id="pulmonary-neuroendocrine-neoplasms" class="level1">
<h1>Pulmonary neuroendocrine neoplasms</h1>
<ul>
<li><strong>Typical carcinoid</strong></li>
<li><strong>Atypical carcinoid</strong></li>
<li><strong>Small cell carcinoma</strong></li>
<li><strong>5- and 10-year survival rates</strong>
<ul>
<li><strong>Typical carcinoids: Above 85%</strong></li>
<li><strong>Atypical carcinoids: 56% and 35%</strong></li>
<li><strong>Small CLC: 5% in 10yr</strong></li>
</ul></li>
</ul>
</section>
<section id="carcinoid-tumors" class="level1">
<h1>Carcinoid Tumors</h1>
<ul>
<li><p><strong>Malignant tumors</strong></p></li>
<li><p><strong>Dense-core neurosecretory granules in cytoplasm</strong></p>
<ul>
<li><strong>Rarely, may secrete hormonally active polypeptides</strong></li>
</ul></li>
<li><p><strong>Typical (low-grade)</strong></p></li>
<li><p><strong>Atypical (intermediate-grade) carcinoids</strong></p></li>
<li><p><strong>Both are often resectable and curable</strong></p></li>
<li><p><strong>Part of the multiple endocrine neoplasia syndrome</strong></p></li>
<li><p><strong>Early age (mean 40 years)</strong></p></li>
<li><p><strong>5% of all pulmonary neoplasms</strong></p></li>
<li><p><strong>Originate in main bronchi</strong></p>
<ul>
<li><strong>An obstructing polypoid, spherical, intraluminal mass</strong></li>
<li><strong>A mucosal plaque penetrating the bronchial wall to fan out in the peribronchial tissue</strong>
<ul>
<li><strong>Collar-button lesion</strong></li>
<li><strong>Broad front, reasonably well demarcated</strong></li>
</ul></li>
</ul></li>
<li><p><strong>Peripheral carcinoids are less common</strong></p></li>
<li><p><strong>5-15% metastasized to the hilar nodes at presentation, distant metastases are rare</strong></p></li>
</ul>
<p><img src="img%5CLung-Tumors20.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CLung-Tumors21.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>
<section id="typical-carcinoids" class="level1">
<h1>Typical carcinoids</h1>
<p><strong>Resemble the ones in the intestinal tract</strong></p>
<p><strong>Nests of uniform cells</strong></p>
<p><strong>Regular round nuclei</strong></p>
<p><strong>Salt-and-pepper chromatin</strong></p>
<p><strong>Absent or rare mitoses</strong></p>
<p><strong>Little pleomorphism</strong></p>
</section>
<section id="atypical-carcinoid-tumors" class="level1">
<h1>Atypical carcinoid tumors</h1>
<ul>
<li><strong>Higher mitotic rate</strong>
<ul>
<li><strong>Less than small or large cell carcinomas</strong></li>
</ul></li>
<li><strong>Focal necrosis</strong></li>
<li><strong>Higher incidence of lymph node and distant metastasis than typical carcinoids</strong></li>
<li><strong>TP53 mutations in 20-40% of cases</strong>
<ul>
<li><strong>Differ from typical carcinoid</strong></li>
</ul></li>
</ul>
</section>
<section id="small-cell-lung-carcinomas" class="level1">
<h1>Small cell lung carcinomas</h1>
<ul>
<li><strong>Pale gray</strong></li>
<li><strong>Centrally located masses</strong></li>
<li><strong>Extension into the lung parenchyma</strong></li>
<li><strong>Early involvement of the hilar and mediastinal nodes</strong></li>
<li><strong>Tumor cells</strong>
<ul>
<li><strong>Round to fusiform shape</strong></li>
<li><strong>Scant cytoplasm</strong></li>
<li><strong>Finely granular chromatin</strong></li>
<li><strong>Mitotic figures are frequent</strong></li>
</ul></li>
</ul>
<p><img src="img%5CLung-Tumors22.png" class="img-fluid"></p>
<p><strong>small cell neuroendocrine (oat cell) carcinoma developed in an asbestosis-scarred lung</strong></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
<ul>
<li><strong>Neoplastic cells are usually twice the size of resting lymphocytes</strong></li>
<li><strong>Necrosis is invariably present and may be extensive</strong></li>
<li><strong>Tumor cells are markedly fragile</strong></li>
<li><strong>Fragmentation and “crush artifact” in small biopsy specimens</strong></li>
<li><strong>Nuclear molding</strong>
<ul>
<li><strong>Close apposition of tumor cells that have scant cytoplasm</strong></li>
</ul></li>
<li><strong>Express a variety of neuroendocrine markers</strong></li>
<li><strong>Secrete polypeptide hormones paraneoplastic syndromes</strong></li>
</ul>
<p><strong>deeply basophilic cells and areas of necrosis </strong></p>
<p><img src="img%5CLung-Tumors23.png" class="img-fluid"></p>
<p><strong>basophilic staining of vascular walls due to encrustation by DNA from necrotic tumor cells (Azzopardi effect)</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>
<section id="homework" class="level1">
<h1>Homework</h1>
<p><strong>Dr. Oberndorfer</strong></p>
<p><strong>Learn his life and his contribution to “Istanbul” and “Karzinoide”</strong></p>
<p><img src="img%5CLung-Tumors24.png" class="img-fluid"></p>
</section>

</main>
<!-- /main column -->
<script id="quarto-html-after-body" type="application/javascript">
window.document.addEventListener("DOMContentLoaded", function (event) {
  const toggleBodyColorMode = (bsSheetEl) => {
    const mode = bsSheetEl.getAttribute("data-mode");
    const bodyEl = window.document.querySelector("body");
    if (mode === "dark") {
      bodyEl.classList.add("quarto-dark");
      bodyEl.classList.remove("quarto-light");
    } else {
      bodyEl.classList.add("quarto-light");
      bodyEl.classList.remove("quarto-dark");
    }
  }
  const toggleBodyColorPrimary = () => {
    const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
    if (bsSheetEl) {
      toggleBodyColorMode(bsSheetEl);
    }
  }
  toggleBodyColorPrimary();  
  const icon = "";
  const anchorJS = new window.AnchorJS();
  anchorJS.options = {
    placement: 'right',
    icon: icon
  };
  anchorJS.add('.anchored');
  const isCodeAnnotation = (el) => {
    for (const clz of el.classList) {
      if (clz.startsWith('code-annotation-')) {                     
        return true;
      }
    }
    return false;
  }
  const clipboard = new window.ClipboardJS('.code-copy-button', {
    text: function(trigger) {
      const codeEl = trigger.previousElementSibling.cloneNode(true);
      for (const childEl of codeEl.children) {
        if (isCodeAnnotation(childEl)) {
          childEl.remove();
        }
      }
      return codeEl.innerText;
    }
  });
  clipboard.on('success', function(e) {
    // button target
    const button = e.trigger;
    // don't keep focus
    button.blur();
    // flash "checked"
    button.classList.add('code-copy-button-checked');
    var currentTitle = button.getAttribute("title");
    button.setAttribute("title", "Copied!");
    let tooltip;
    if (window.bootstrap) {
      button.setAttribute("data-bs-toggle", "tooltip");
      button.setAttribute("data-bs-placement", "left");
      button.setAttribute("data-bs-title", "Copied!");
      tooltip = new bootstrap.Tooltip(button, 
        { trigger: "manual", 
          customClass: "code-copy-button-tooltip",
          offset: [0, -8]});
      tooltip.show();    
    }
    setTimeout(function() {
      if (tooltip) {
        tooltip.hide();
        button.removeAttribute("data-bs-title");
        button.removeAttribute("data-bs-toggle");
        button.removeAttribute("data-bs-placement");
      }
      button.setAttribute("title", currentTitle);
      button.classList.remove('code-copy-button-checked');
    }, 1000);
    // clear code selection
    e.clearSelection();
  });
  function tippyHover(el, contentFn) {
    const config = {
      allowHTML: true,
      content: contentFn,
      maxWidth: 500,
      delay: 100,
      arrow: false,
      appendTo: function(el) {
          return el.parentElement;
      },
      interactive: true,
      interactiveBorder: 10,
      theme: 'quarto',
      placement: 'bottom-start'
    };
    window.tippy(el, config); 
  }
  const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
  for (var i=0; i<noterefs.length; i++) {
    const ref = noterefs[i];
    tippyHover(ref, function() {
      // use id or data attribute instead here
      let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
      try { href = new URL(href).hash; } catch {}
      const id = href.replace(/^#\/?/, "");
      const note = window.document.getElementById(id);
      return note.innerHTML;
    });
  }
      let selectedAnnoteEl;
      const selectorForAnnotation = ( cell, annotation) => {
        let cellAttr = 'data-code-cell="' + cell + '"';
        let lineAttr = 'data-code-annotation="' +  annotation + '"';
        const selector = 'span[' + cellAttr + '][' + lineAttr + ']';
        return selector;
      }
      const selectCodeLines = (annoteEl) => {
        const doc = window.document;
        const targetCell = annoteEl.getAttribute("data-target-cell");
        const targetAnnotation = annoteEl.getAttribute("data-target-annotation");
        const annoteSpan = window.document.querySelector(selectorForAnnotation(targetCell, targetAnnotation));
        const lines = annoteSpan.getAttribute("data-code-lines").split(",");
        const lineIds = lines.map((line) => {
          return targetCell + "-" + line;
        })
        let top = null;
        let height = null;
        let parent = null;
        if (lineIds.length > 0) {
            //compute the position of the single el (top and bottom and make a div)
            const el = window.document.getElementById(lineIds[0]);
            top = el.offsetTop;
            height = el.offsetHeight;
            parent = el.parentElement.parentElement;
          if (lineIds.length > 1) {
            const lastEl = window.document.getElementById(lineIds[lineIds.length - 1]);
            const bottom = lastEl.offsetTop + lastEl.offsetHeight;
            height = bottom - top;
          }
          if (top !== null && height !== null && parent !== null) {
            // cook up a div (if necessary) and position it 
            let div = window.document.getElementById("code-annotation-line-highlight");
            if (div === null) {
              div = window.document.createElement("div");
              div.setAttribute("id", "code-annotation-line-highlight");
              div.style.position = 'absolute';
              parent.appendChild(div);
            }
            div.style.top = top - 2 + "px";
            div.style.height = height + 4 + "px";
            let gutterDiv = window.document.getElementById("code-annotation-line-highlight-gutter");
            if (gutterDiv === null) {
              gutterDiv = window.document.createElement("div");
              gutterDiv.setAttribute("id", "code-annotation-line-highlight-gutter");
              gutterDiv.style.position = 'absolute';
              const codeCell = window.document.getElementById(targetCell);
              const gutter = codeCell.querySelector('.code-annotation-gutter');
              gutter.appendChild(gutterDiv);
            }
            gutterDiv.style.top = top - 2 + "px";
            gutterDiv.style.height = height + 4 + "px";
          }
          selectedAnnoteEl = annoteEl;
        }
      };
      const unselectCodeLines = () => {
        const elementsIds = ["code-annotation-line-highlight", "code-annotation-line-highlight-gutter"];
        elementsIds.forEach((elId) => {
          const div = window.document.getElementById(elId);
          if (div) {
            div.remove();
          }
        });
        selectedAnnoteEl = undefined;
      };
      // Attach click handler to the DT
      const annoteDls = window.document.querySelectorAll('dt[data-target-cell]');
      for (const annoteDlNode of annoteDls) {
        annoteDlNode.addEventListener('click', (event) => {
          const clickedEl = event.target;
          if (clickedEl !== selectedAnnoteEl) {
            unselectCodeLines();
            const activeEl = window.document.querySelector('dt[data-target-cell].code-annotation-active');
            if (activeEl) {
              activeEl.classList.remove('code-annotation-active');
            }
            selectCodeLines(clickedEl);
            clickedEl.classList.add('code-annotation-active');
          } else {
            // Unselect the line
            unselectCodeLines();
            clickedEl.classList.remove('code-annotation-active');
          }
        });
      }
  const findCites = (el) => {
    const parentEl = el.parentElement;
    if (parentEl) {
      const cites = parentEl.dataset.cites;
      if (cites) {
        return {
          el,
          cites: cites.split(' ')
        };
      } else {
        return findCites(el.parentElement)
      }
    } else {
      return undefined;
    }
  };
  var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
  for (var i=0; i<bibliorefs.length; i++) {
    const ref = bibliorefs[i];
    const citeInfo = findCites(ref);
    if (citeInfo) {
      tippyHover(citeInfo.el, function() {
        var popup = window.document.createElement('div');
        citeInfo.cites.forEach(function(cite) {
          var citeDiv = window.document.createElement('div');
          citeDiv.classList.add('hanging-indent');
          citeDiv.classList.add('csl-entry');
          var biblioDiv = window.document.getElementById('ref-' + cite);
          if (biblioDiv) {
            citeDiv.innerHTML = biblioDiv.innerHTML;
          }
          popup.appendChild(citeDiv);
        });
        return popup.innerHTML;
      });
    }
  }
});
</script>
</div> <!-- /content -->



</body></html>